Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,102
  • Shares Outstanding, K 57,979
  • Annual Sales, $ 26,290 K
  • Annual Income, $ -29,320 K
  • 60-Month Beta 1.60
  • Price/Sales 1.65
  • Price/Cash Flow N/A
  • Price/Book 1.24
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/07/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +1,248,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.74 +7.89%
on 10/11/19
0.92 -13.10%
on 09/20/19
-0.07 (-8.10%)
since 09/13/19
3-Month
0.63 +26.80%
on 08/09/19
0.92 -13.10%
on 09/20/19
unch (-0.06%)
since 07/12/19
52-Week
0.60 +33.25%
on 12/24/18
2.11 -62.11%
on 10/15/18
-1.14 (-58.79%)
since 10/12/18

Most Recent Stories

More News
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment candidate, pacritinib. The...

CTIC : 0.80 (+2.56%)
CTI BioPharma Reports Second Quarter 2019 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2019.

CTIC : 0.80 (+2.56%)
CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis

CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI" or "the Company") today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency") for the continued...

CTIC : 0.80 (+2.56%)
CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference at 4:30 p.m. EDT in New York City.

CTIC : 0.80 (+2.56%)
CTI BioPharma Reports First Quarter 2019 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019.

CTIC : 0.80 (+2.56%)
Research Report Identifies Fastenal, Ideal Power, Fuel Tech, CTI BioPharma, Aptevo Therapeutics, and Caseys General Stores with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fastenal Company (NASDAQ:FAST),...

FAST : 35.98 (-0.99%)
IPWR : 2.95 (+35.32%)
FTEK : 0.94 (-4.08%)
CTIC : 0.80 (+2.56%)
APVO : 0.56 (-1.75%)
CASY : 161.88 (+0.27%)
CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New...

CTIC : 0.80 (+2.56%)
CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018.

CTIC : 0.80 (+2.56%)
CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29th Annual Healthcare Conference at 4:30 p.m. EDT at the Westin New...

CTIC : 0.80 (+2.56%)
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows...

CTIC : 0.80 (+2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade CTIC with:

Business Summary

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its...

See More

Key Turning Points

2nd Resistance Point 0.82
1st Resistance Point 0.80
Last Price 0.80
1st Support Level 0.75
2nd Support Level 0.72

See More

52-Week High 2.11
Fibonacci 61.8% 1.53
Fibonacci 50% 1.36
Fibonacci 38.2% 1.18
Last Price 0.80
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar